Roche cancer drugs drive healthy sales rise PharmaTimes The top-selling drug was MabThera/Rituxan (rituximab), approved for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arthritis, contributed 1.80 billion francs in the oncology setting, an increase of 12%. Sales of ... |
